Abstract:TPS488 Background: Renal cell carcinoma (RCC) has a biologic propensity for vascular invasion leading to a venous tumor thrombus (VTT) in the renal vein or inferior vena cava (IVC) in up to 25% of cases. RCC with VTT is a poor prognostic factor for cancer-related mortality. Additionally, depending on the tumor burden and extent of the tumor thrombus (TT), patients can become symptomatic from the VTT, affecting patients’ quality of life. The current standard of care for RCC with an IVC TT is to undergo a radical nephrectomy with an IVC thrombectomy which may be associated with high surgical morbidity and mortality. We hypothesize that the combination of PEMBRO and AXI given in the neoadjuvant setting will decrease the IVC TT burden. The KEYNOTE-426 trial evaluated the combination of PEMBRO and AXI in the metastatic setting which showed an objective response rate of 59.3%. Thus, it is reasonable to consider a response in the overall burden of disease, inclusive of the VTT. This decrease in size of the VTT can potentially lead to decreased surgical complications, improve patient-related outcomes, and improve progression-free survival (PFS) and overall survival (OS). Methods: This single-center, open-label, single-arm phase II trial is enrolling patients with clear cell RCC that demonstrate IVC TT. The primary endpoint is the IVC TT response (change in size) after neoadjuvant PEMBRO and AXI. The extent of IVC TT will be measured by the Mayo classification and cross-sectional dimensions. Secondary endpoints include surgical complications/morbidity per Clavien-Dindo classification, 1-year PFS, 1-year OS, and safety of PEMBRO and AXI. Correlative analysis of pre and post operative tumor samples will also be performed. Patients will receive the combination of PEMBRO 200 mg intravenously and AXI 5 mg orally twice daily every 21 days for 4 cycles. A radiographic assessment will be performed at baseline and after up to 12 weeks (4 cycles) of therapy to evaluate the primary endpoint of IVC TT response. Patients will undergo a definitive surgery per treating urologist within 2 weeks (+/- 7 days) after this evaluation. Patients will have at least cT3b tumor with or without lymph node or distant metastases and a biopsy confirming a component of clear cell RCC. The study will include patients who are candidates for upfront surgery as determined by their treating urologist. A Simon’s two-stage design will be utilized with the first stage enrolling 9 subjects. If there are zero responses, the trial will be stopped. If there are 3 or more patients that are not able to undergo surgery due to treatment-related adverse events, enrollment will be paused. If neither of these occur, we will enroll 8 additional subjects, rejecting the null hypothesis of an IVC response in only 5% of patients if we observe at least 3 of 17 patients with a measured reduction from baseline size of the TT. Clinical trial information: NCT05969496 .

A Phase II study of neoadjuvant axitinib for reducing the extent of venous tumour thrombus in clear cell renal cell cancer with venous invasion (NAXIVA)

Angiogenic and Immune Predictors of Neoadjuvant Axitinib Response in Renal Cell Carcinoma with Venous Tumour Thrombus

Neoadjuvant toripalimab plus axitinib for clear cell renal cell carcinoma with inferior vena cava tumor thrombus: NEOTAX, a phase 2 study

Updated efficacy results from the JAVELIN Renal 101 trial: first-line avelumab plus axitinib versus sunitinib in patients with advanced renal cell carcinoma

A Phase II Trial of Sitravatinib Plus Nivolumab after Progression on Prior Immune Checkpoint Inhibitor (ICI) in Patients with Metastatic Clear Cell Renal Cell Carcinoma (Ccrcc).

Phase II Clinical Trial of Axitinib and Avelumab in Patients With Recurrent/Metastatic Adenoid Cystic Carcinoma

Neoadjuvant pembrolizumab (PEMBRO) and axitinib (AXI) in renal cell carcinoma with associated inferior vena cava tumor thrombus (NEOPAX).

ATLAS Study: A Randomized Double-Blind Phase 3 Study of Adjuvant Axitinib Versus Placebo in Subjects at High Risk of Recurrent Renal Cell Carcinoma (RCC).

Extended follow-up from JAVELIN Renal 101: subgroup analysis of avelumab plus axitinib versus sunitinib by the International Metastatic Renal Cell Carcinoma Database Consortium risk group in patients with advanced renal cell carcinoma

A phase II study of neoadjuvant tislelizumab and axitinib in patients with locally advanced non-metastatic clear cell renal cell carcinoma (accRCC).

Phase II study of axitinib intensification compared to nivolumab alone after induction with ipilimumab plus nivolumab in patients with mRCC without previous complete response (AxIn study).

Phase II study of axitinib prior to partial nephrectomy to preserve renal function: An interim analysis of the PADRES clinical trial.

Neoadjuvant toripalimab combined with axitinib in patients with locally advanced clear cell renal cell carcinoma: a single-arm, phase II trial

PADRES: a phase 2 clinical trial of neoadjuvant axitinib for complex partial nephrectomy

NFS-11. PHASE II STUDY OF AXITINIB IN PATIENTS WITH NEUROFIBROMATOSIS TYPE 2-RELATED SCHWANNOMATOSIS AND PROGRESSIVE VESTIBULAR SCHWANNOMAS

Phase II trial of neoadjuvant sitravatinib plus nivolumab in patients undergoing nephrectomy for locally advanced clear cell renal cell carcinoma

Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

Efficacy of avelumab plus axitinib (A + Ax) versus sunitinib (S) by number of IMDC risk factors and tumor sites at baseline in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

Tivozanib plus nivolumab versus tivozanib monotherapy in patients with renal cell carcinoma following an immune checkpoint inhibitor: results of the phase 3 TiNivo-2 Study

Axitinib Versus Placebo As an Adjuvant Treatment of Renal Cell Carcinoma: Results from the Phase III, Randomized ATLAS Trial

Activity of Tivozanib in Non-clear Cell Renal Cell Carcinoma: Subgroup Analysis From a Phase II Randomized Discontinuation Trial